CMC Pharma Consulting BJ ApS: Financial statements 2024
CVR: 41988592
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
CMC Pharma Consulting BJ ApS (CVR 41988592) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 1,006,532 and a net result of DKK 127,570 compared with DKK 111,571 the year before. That is a decrease of 79.7% compared with the year before. Equity in the 2024 report amounted to DKK 215,537. The solvency ratio was 72.6%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 1,006,532
- Profit/Loss
- DKK 127,570
- Equity
- DKK 215,537
- Total Assets
- DKK 297,059
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 1M | 128K | 216K | 2 |
| 2023 | - | 4.9M | 112K | 208K | 1 |
| 2022 | - | 5.2M | 345K | 396K | 1 |
| 2021 | - | 3.5M | 611K | 651K | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
CMC Pharma Consulting BJ ApS has published its annual report for 2023. Gross profit came to DKK 4,949,668, and the net result was DKK 111,571.
About CMC Pharma Consulting BJ ApS
CMC Pharma Consulting BJ ApS is a Danish company of the type Anpartsselskab based in Rungsted Kyst, founded in 2021. The company is registered under the industry Anden teknisk rådgivning. The management consists of Babak Jamali. The company is owned by Babak Jamali. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 1,764,114 and a net result of DKK 30,653 compared with DKK 127,570 the year before. Equity in the 2025 report amounted to DKK 111,190.